sar425899 dual agonist glp-1 glucagon sanofi The molecular pharmacology of agonists in diabetes and obesity Glucagon agonism in the treatment

EMPA-REG vs SURPASS Clinical Trial Data EMPA-REG OUTCOME (n=7,020): This landmark cardiovascular outcomes trial, published in The New England Journal of Medicine, randomized patients with type 2 diabetes and established cardiovascular disease to Jardiance or placebo

Larkin et al v

In addition to the direct nephroprotective effect, GLP-1R agonists have indirect protective effects as they decrease the incidence of many risk factors associated with kidney injury

doi: 10.2337/db15-0443

Rather, its a number created for you by your PBM to optimize its profit off of the management of your drug benefit

Whether tapering actually reduces total weight regain remains unproven